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Resistance to radiotherapy in glioblastoma (GBM) is an important clinical problem and
several authors have attributed this to a subpopulation of GBM cancer stem cells (CSCs)
which may be responsible for tumour recurrence following treatment. It is hypothesised
that GBM CSCs exhibit upregulated DNA damage responses and are resistant to radiation
but the current literature is conflicting. We investigated radioresistance of primary GBM
cells grown in stem cell conditions (CSC) compared to paired differentiated tumour cell
populations and explored the radiosensitising effects of the ATM inhibitor KU-55933.
We report that GBM CSCs are radioresistant compared to paired differentiated tumour cells
as measured by clonogenic assay. GBM CSC’s display upregulated phosphorylated DNA
damage response proteins and enhanced activation of the G2/M checkpoint following irra-
diation and repair DNA double strand breaks (DSBs) more efficiently than their differenti-
ated tumour cell counterparts following radiation.
Inhibition of ATM kinase by KU-55933 produced potent radiosensitisation of GBM CSCs
(sensitiser enhancement ratios 2.6e3.5) and effectively abrogated the enhanced DSB repair
proficiency observed in GBM CSCs at 24 h post irradiation. G2/M checkpoint activation was
reduced but not abolished by KU-55933 in GBM CSCs.
ATM kinase inhibition overcomes radioresistance of GBM CSCs and, in combination with
conventional therapy, has potential to improve outcomes for patients with GBM.
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12e16 months (Stupp et al., 2005). To improve the dismal sur-
vival figures, however, the mechanisms underlying radiore-
sistance must be further elucidated and strategies developed
to overcome them. Dominant clonal populations, which
emerge as a result of genetic and epigenetic changes that
confer a survival advantage, are thought to drive tumour
growth (Bonavia et al., 2011; Nowell, 1976; Patel et al., 2014).
The stochastic basis of this clonal evolution model has
recently been challenged by the cancer stem cell (CSC) hy-
pothesis (Reya et al., 2001). According to this hypothesis
tumour growth is driven by a hierarchically organised popula-
tion of tumourigenic cells that, similar to normal stem cells,
self-renew and generate non-tumourigenic progeny.
Although widely accepted, this hypothesis remains conten-
tious. Data identifying the glycoprotein CD133 as a putative
CSC marker in GBM (Bao et al., 2006; Galli et al., 2004; Singh
et al., 2004) have been challenged (Beier et al., 2007; Joo
et al., 2008; Kelly et al., 2009; Son et al., 2009) and the case
for a cellular hierarchical organisation in GBM remains
unproven.
Nevertheless, research has been facilitated by the identifi-
cation of molecular markers that have been reported to iden-
tify tumour propagating/CSCs in vitro. CD133, Sox 2 and Nestin
are commonly utilised, however it is likely that these markers
identify GBM clonal populations which are heterogeneous in
their tumorigenic potential. In keeping with this, a recent
study has identified via single cell RNA sequencing a contin-
uum of stemness-related expression states within single
GBM tumours (Patel et al., 2014) suggesting that the cancer
stem cell state displays significant plasticity. Functional as-
says of enhanced tumourigenicity remain the most useful in-
dicator of stemness in GBM cell populations and the study of
GBM CSCs relies upon the use of patient derived cell lines of
low passage in order to prevent clonal drift.
The commonly observed clinical scenario of initial
response to treatment followed by inevitable local recurrence
may be explained by the failure of current therapies to steri-
lise CSCs, and several researchers have investigated whether
CSCs are resistant to cytotoxic therapy. Chen et al. identified
GBM initiating cells that were capable of repopulating GBM tu-
mours in vivo following temozolomide treatment (Chen et al.,
2012). Responses of GBM CSCs to radiotherapy have also been
investigated, with conflicting results. Bao et al. demonstrated
that CD133þ tumour cell populations were radioresistant
compared to CD133 populations (Bao et al., 2006), a pheno-
type that was mediated by upregulation of the DNA damage
response (DDR). Enhanced phosphorylation of cell cycle
checkpoint proteins was demonstrated along with evidence
of more efficient DNA repair, although the kinetics of DNA
double strand break (DSB) repair were not examined in detail.
In contrast, McCord et al. reported radiosensitivity and defec-
tive DDR in CD133þ tumour cell populations (McCord et al.,
2009), but comparison of CD133þ populations with unrelated,
established GBM cell lines may not be an optimal model.
Ropolo et al. conducted a comparative analysis of DNA repair
in stem and non-stem GBM cultures and found no evidence of
enhanced DNA repair, although CD133þ cells had a prolonged
cell doubling time along with enhanced cell cycle checkpoint
protein activation (Ropolo et al., 2009).Small molecule inhibitors of DDR proteins have been
demonstrated to increase the radiosensitivity of tumour cells
in pre-clinical studies. Many tumours are defective in DDR
when compared to normal tissues (Bartkova et al., 2005), and
targeting tumour-specific DDR deficiencies to enhance radio-
sensitivity of tumour cells is an attractive clinical strategy.
Ataxia telangiectasia mutated (ATM) is a key DDR component,
playing a central role in DSB repair and cell cycle checkpoints
(Shiloh and Ziv, 2013). Deficiency of ATM function causes
Ataxia Telangiectasia which is characterised by increased ra-
diation sensitivity (Taylor et al., 1975) and inhibition of ATM
kinase activity causes potent radiosensitisation of GBM cells
(Biddlestone-Thorpe et al., 2013; Golding et al., 2012, 2009).
The ATM-Chk2 pathway is known to have particular impor-
tance in the molecular pathogenesis of GBM. In the first study
of endogenous DNA damage signalling in glioma, it was re-
ported that whilst gammaH2AXwas upregulated in all grades
of glioma, robust activation of the ATM-Chk2 pathway was
only observed in GBM (Bartkova et al., 2010). Hence inhibition
of ATM has potential applications in the treatment of GBM,
but detailed investigation of their radiosensitising effects in
GBM CSC’s and the underlying mechanisms has not yet been
reported.
We characterised the radioresistant properties of primary
GBM cell cultures propagated as paired cell lines either in
serum free, stem cell promoting (“cancer stem cell”; CSC) con-
ditions or in serum-containing, stem cell depleting differenti-
ating culture conditions (“differentiated tumour cells”; diff) in
order to compare GBM cancer stem cells (CSCs) with differen-
tiated (or “non-stem”) GBM cells originating from the same
parental tumour. Herein we report increased radioresistance
of GBM CSC populations relative to differentiated cell popula-
tions that is associatedwith an enhancedDNA damage check-
point response as well as an increased capacity for DSB repair.
Consistent with published data we observed upregulation of
ATM activity in GBM CSC’s and report the novel observation
that ATM inhibition potently radiosensitises GBM CSC’s. A
detailed analysis of the cell cycle checkpoint and DSB repair
mechanisms underlying this effect is also presented.2. Methods
2.1. Patient-derived GBM cell derivation and culture
R10, S2, E2 andG7 primary glioblastoma cell lineswere derived
from freshly resected GBM specimens as previously described
(Fael Al-Mayhani et al., 2009). Tissue collection protocols were
compliant with the UK Human Tissue Act 2004 (HTA Licence
ref 12315) and approved by the local regional Ethics Commit-
tee (LREC ref 04/Q0108/60). Informed consent was obtained
from each patient before surgery. Briefly, anonymised patient
resection specimens were homogenised and seeded in serum
free (SF) media to form spheroid aggregates which were then
collected and plated onto extracellular matrix coated
flasks (ECM 1:10 dilution, Sigma). Cells were allowed to form
a primary monolayer then passaged in SF medium. Each cell
line was subsequently cultured as paired populations grown
either in stem cell enriching conditions (CSC) or in
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 9 2e2 0 3194differentiating conditions (diff) by passaging in SF media or
differentiating media (DM) respectively. SF media consisted
of Adv DMEM F12 medium (Gibco) supplemented with 1%
B27 (Invitrogen), 0.5% N2 (Invitrogen), 4 mg/ml heparin,
20 ng/ml fibroblast growth factor 2 (bFGF, Sigma), 20 ng/ml
epidermal growth factor (EGF, Sigma) and 1% L-Glutamine.
DM consisted of MEM (Gibco) supplemented with 10% foetal
bovine serum (FBS) Sigma, 1% L-glutamine and 1% sodium py-
ruvate. CSC cultures were grown as monolayers on Matrigel
coated flasks in SF media. Neurosphere cultures were grown
in identical media in 96 well plates without Matrigel. Differ-
entiated tumour cell cultures were grown as adherent mono-
layers in uncoated flasks in FCS containing media. All cell
cultures were maintained at 37 C, 5% CO2 and routinely
passaged every 3e4 days. For all experiments, low passage
number cells were used (maximum 20 but more commonly 5
to 15 passages).
Cells cultured in neurobasal SF conditions exhibited upre-
gulated expression of the cancer stem cell markers CD133,
Nestin and Sox2 compared with differentiated tumour cul-
tures. CSC enriched cultures of G7 and E2 cells were tumori-
genic after intracranial injection in CD1 nude mice. Injection
of 1  105 E2 cells generated highly infiltrative tumours that
resemble gliomatosis cerebri; tumour burdenwas significantly
greater after injection of CSC enrichedpopulations than differ-
entiated tumour cell populations. CSC enriched cultures of G7
cells generated intracranial tumours that recapitulated key
histological features of GBM and demonstrated an invasive
phenotype whereas differentiated tumour cells generated
well-demarcated,non-invasive tumours (Manninoet al., 2014).
2.2. Irradiation
Cultures were irradiated in tissue culture flasks at room tem-
perature with 195 kV X-rays at a dose rate of 1.6 Gy/min in an
Xstrahl RS225 cabinet.
2.3. ATM inhibitor
The ATM inhibitor KU-55933 (Tocris Bioscience) was solubi-
lised in 100% DMSO to produce a 100 mM stock. In all experi-
ments cells were exposed to 10 mM KU-55933 for 1 h prior to
irradiation. Controls were exposed to media containing
0.01% DMSO.
2.4. Clonogenic assays
GBM CSC and differentiated tumour cell cultures were seeded
at a density of 250 cells per well in Matrigel-coated 6 well
dishes. CSC and differentiated tumour cultures were main-
tained in SF or DM respectively for the duration of the assay.
Cellswere incubated for 24 h then exposed to freshmedia con-
taining either 10 mM KU-55933 or 0.01% DMSO for 1 h before
irradiation (1e5 Gy) or sham irradiation. Cells were then incu-
bated for a further 24 h before aspiration of drug containing
media and replacement with fresh media. G7 cells were incu-
bated for 2 weeks and R10 and E2 cells for 3 weeks prior to fix-
ation and staining. Colonies of diameter 50 cells or greater
were counted using an automated colony counter (GelCount,
Oxford Optronix).2.5. Neurosphere assays
GBM CSC were plated at a density of 10 cells per 100 mL me-
dium per well in 96 well plates in SF media containing 10 mM
KU-55933 or 0.01% DMSO and irradiated (2 Gy) or sham irradi-
ated. Cultures were incubated for a further 48 h and a further
100 mL of fresh media was added. Neurospheres were counted
manually under 5 magnification after 4 weeks and 3 weeks
for E2 and G7 cells respectively.
2.6. Gamma H2AX foci quantification
E2 GBM CSC and differentiated tumour cells were plated on
coverslips and exposed to 10 mMKU-55933 or an identical con-
centration of vehicle and treatedwith 1 Gy or sham irradiated.
Cultures were fixed in 4% formaldehyde/PBS then permeabi-
lised, blocked with 5% FCS, 0.5% BSA in 0.1% Triton-PBS and
incubated with anti-gamma H2AX (Millipore, 1:100) and
CENPF (Abcam, 1:250) antibodies overnight at 4 C then with
appropriate Alexa Fluor 568 or 488 secondary antibodies (Invi-
trogen). Nuclei were counterstained with DAPI.
Z-stacks were obtained at 63magnification on a Zeiss 710
confocal microscope. 30 Z-stacks at each time point/condition
were acquired for analysis. Volocity software was used to
identify and count foci in each nucleus. Nuclei were categor-
ised into “moderate/strongly positive for CENPF” and “weak/
negative for CENPF” by the operator. Nuclei which exhibited
confluent staining for gamma H2AX were assumed to be in S
phase and were excluded from the analysis. The number of
nuclei analysed for each data point ranged from 65 to 307
(CENPF positive) and 300 to 460 (CENPF negative).
2.7. FACS analysis
G7, S2 and E2 CSC and differentiated tumour cultures were
irradiated with 5 Gy  KU-55933. Cultures were disaggregated
with Accutase and fixed in 70% ethanol.
Fixed cells were pelleted and incubated with anti-
phosphorylated Histone H3 serine 10 antibody Alexa Fluor
488 conjugate 1:50 (Cell Signaling). Cells were resuspended
in 1 mg/ml propidium iodide solution with RNAase A. FACS
analysis was carried out on a FACSCalibur and results ana-
lysed using FlowJo 7.6.5.
2.8. Western blotting
Cultures were exposed to 10 mM KU-55933 or vehicle and irra-
diated with 5 Gy. Total cell lysates were prepared using SDS
lysis buffer. Lysates were blotted onto membrane and probed
with antibodies specific for phosphorylated ATM serine 1981
(Novus Biologicals), phosphorylated Chk2 threonine 68 (Cell
Signaling) (Supplementary Figure 2C).
2.9. Cell proliferation assay
Cells were seeded onto 96 well plates. A range of concentra-
tions of KU-55933 was added to each well. An ATP based cell
viability assay was then carried out at 24 h and 6 days
following addition of drug according to manufacturer’s in-
structions (CellTiter-Glo, Promega).
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All experiments were repeated 3 times except where stated
and data points reported as mean  SEM. The unpaired t-
test or one sample t test were used to generate p values.
Gamma H2AX foci data was analysed using median foci
counts per nucleus derived from 3 independent experiments.
Mann Whitney tests were used to test significance because
foci counts were not normally distributed, exhibiting signifi-
cant positive skew when plotted as a histogram. A linear
quadratic fitwas applied to clonogenic data, and SER0.37 values
were calculated from fitted data. The ANOVA test was used to
analyse differences in clonogenic survival curves. Minitab and
GraphPad Prism were used for analyses.3. Results
3.1. GBM CSC cultures are radioresistant in comparison
to GBM differentiated tumour cell cultures
To evaluate radiation sensitivity, clonogenic survival assays
were performed using R10, E2 and G7 cell lines. To minimise
the impact of the different culture conditions, all experiments
were conducted using Matrigel-coated plates. Under these
conditions plating efficiency of CSC and differentiated tumour
populations were similar, although subtle differences in col-
ony morphology between CSC and differentiated tumour cell
cultures were noted (Figure 1A). While both CSC and tumour
differentiated cultures exhibited radioresistance, GBM CSC
enriched cultures were significantly more resistant to radia-
tion (1e5 Gy) than differentiated tumour cell cultures
(Figure 1A). Although radioresistance of GBM CSC has been re-
ported previously (Bao et al., 2006; Venere et al., 2014), to our
knowledge this is the first demonstration of this phenotype
in paired cell lines using clonogenic survival assays. Curves
were fitted with the linear quadratic equation and dose modi-
fying factors at a surviving fraction of 37% calculated (Table
1A). These showed that the dose of radiation required to pro-
duce an equivalent decrease in surviving fraction was 1.5 fold
greater for R10 CSC (p < 0.0001), 1.3 fold greater for E2 CSC
(p < 0.001) and 1.5 fold greater for G7 CSC (p ¼ 0.015) than for
the corresponding differentiated tumour cell cultures. Surviv-
ing fraction at 4 Gy (SF4Gy) values were also statistically signif-
icantly higher in R10, E2 and G7 CSC populations than in
corresponding differentiated tumour cell populations (Table
1B) confirming the radioresistant phenotype of these stem
cell enriched primary glioblastoma cell populations. Mean
SF4Gy for E2 CSC and tumour differentiated cells were 0.62
and 0.46 respectively (p ¼ 0.001), and 0.63 compared to 0.46
for G7 CSC and differentiated tumour cell populations respec-
tively (p ¼ 0.05). A similar significant difference was seen be-
tween CSC and differentiated tumour cells derived from
primary R10 GBM cell cultures. SF4Gy values have been cited
rather than the more conventional SF2Gy values because the
inherent radioresistance of the cell populations rendered cal-
culations based on the latter parameter lessmeaningful. Since
radiotherapy is usually delivered in daily 2 Gy fractions, how-
ever, SF2Gy is a more clinically relevant parameter and it is ofinterest to note that this value was between 83% and 90% in
the three GBM CSC populations tested. Analysis of the CSC
and differentiated tumour cell survival curves by ANOVA
demonstrated a statistically significant difference in all three
cell lines (p < 0.001).
3.2. Glioblastoma CSC enriched cultures exhibit an
enhanced DNA damage response following exposure to
ionising radiation
To investigate themechanisms underlying the radiation resis-
tance of GBM CSC and examine the hypothesis that the DNA
damage response contributes to this phenotype as previously
reported, we interrogated a panel of DNA damage response
proteins. ATM represents a key hub of the DNA damage
response having roles in both cell cycle control and DNA
repair. As a biochemical readout we measured phosphoryla-
tion of ATM at serine 1981 and Chk2 at threonine 68 in cell cul-
tures following exposure to radiation. Serine 1981 is an
autophosphorylation site of ATM which correlates with acti-
vation of DDR while Chk2 is a major phosphorylation target
of ATM and an important mediator of cell cycle checkpoints
following ionising radiation.
Western blot analysis revealed an upregulated DDR in CSC
enriched cultures compared to differentiated tumour cell cul-
tures. Ionising radiation (5 Gy) induced a robust pATM s1981
and pChk2 thr68 response in E2 CSC cultures at 1, 3 and 6 h,
whereas this response was less prominent in E2 differentiated
tumour cell cultures (Figure 1B). A similar pattern in upregula-
tion of pATM and pChk2 was seen in R10 CSCs when
compared to R10 differentiated tumour cells 1 h after radia-
tion. In the absence of radiation, upregulation of pATM
s1981 and pChk2 thr68 was also evident in G7 CSC cultures
compared to G7 differentiated tumour cell cultures. Indeed,
the predominant effect in G7 CSC appeared to be upregulation
of baseline levels of pATM rather than additional upregulation
of the pATM response following radiation.
Wehypothesised that these differentDDR responseswould
translate intodifferent cell cycle checkpoint activationkinetics
following IR. Neither E2 nor G7 cells exhibited a G1/S check-
point response to ionising radiation (Supp Figure 1), so we
quantified radiation inducedactivationof theG2/Mcheckpoint
by flow cytometric analysis of phosphorylated histone H3 at
serine 10, a specific marker of mitotic cells. E2, G7 and S2
GBM CSC cultures all displayed enhanced activation of the
G2/M checkpoint at 3 and 6 h following radiation compared
with differentiated tumour cell populations; this was mani-
fested by a rapid fall in the percentage of mitotic cells in the
CSC populations (Figure 2A). These data demonstrate for the
first time that the cell cycle checkpoint phosphoprotein
changes in GBM CSCs described here and published
previously (Bao et al., 2006) result in enhanced cell cycle check-
point activation in GBM CSCs. This phenomenon is likely to
contribute to the radioresistant phenotype of GBM CSCs.
3.3. Resolution of gamma H2AX foci induced by ionising
radiation is enhanced in glioblastoma CSC populations
Alongside cell cycle checkpoint activation, repair of radiation
induced DNA breaks is a key determinant of radiation
Figure 1 e A, Clonogenic survival curves showing response of CSC and differentiated tumour cell cultures to ionising radiation in R10, E2 and G7
primary cell cultures. Mean surviving fraction plus SEM of 9 independent experiments is shown for E2 and G7, whilst means of 3 independent
experiments are shown for R10 fitted to a linear quadratic model. Curves are significantly different by ANOVA (E2 CSC vs differentiated tumour
cells p< 0.001, G7 CSC vs differentiated tumour cells p< 0.001, R10 CSC vs differentiated tumour cells p< 0.0001). Representative images of
colony formation at 0 and 4 Gy in each population are shown. B, Western blots comparing levels of pATM s1981 and pChk2 thr 68 at 0, 1, 3 and
6 h following 5 Gy of ionising radiation in E2 and G7 CSC and differentiated tumour cell populations. Levels of pATM and pChk2 are shown at
1 h post 5 Gy in the R10 cell line.
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critical lesions. To investigate whether DSB repair contributes
to the relative radioresistance of our GBM CSC populations we
conducted a detailed, quantitative analysis of induction and
resolution of nuclear gamma H2AX foci in E2 CSC and differ-
entiated tumour cells following exposure to ionising radiation
(1 Gy, Figure 2). Since cells in G2 phase have increased DNA
content and therefore exhibit approximately twice as many
DSB per Gy compared to cells in G1, separate analyses were
conducted for cells staining positively and negatively for
CENPF, which is a marker of cells in G2 phase. S phase cells
exhibit diffuse gamma H2AX staining and were excluded
from the analysis. This approach enabled us to exclude any in-
fluence of cell cycle phase on foci counts.
No difference in induction of gammaH2AX foci between E2
CSC and differentiated tumour cell cultures was observed at
1 h, and the early or ‘fast’ kinetics of foci resolution did not
differ between populations when measured at the 3 h time
point (Figure 2B). However, E2 GBM CSC cultures displayed asignificantly enhanced ability to resolve DNA DSBs at 24 h
compared to E2 differentiated tumour cell cultures. This
enhanced repair of a subset of DSBs was evident in both
CENPF negative and CENPF positive populations of cells: me-
dian number of gamma H2AX foci at 24 h was 3 in differenti-
ated tumour cells versus 1 in CSC in CENPF negative cells
(p < 0.001) and 11 in differentiated tumour cells versus 7in
CSC in CENPF positive cells (p ¼ 0.0001). Unirradiated CENPF
positive E2 CSCs exhibited a small but statistically significant
increase in median number of foci compared to unirradiated
differentiated tumour cell cultures (median gamma H2AX
foci 6 in CSC versus 3 in differentiated tumour cells,
p ¼ 0.004, Figure 2B). This difference was not evident in CENPF
negative cells.
These data provide the most detailed evidence to date of a
modest but significant increase in the ability of GBM CSC to
execute repair of a subset of DSB. That this enhanced repair
capacity was observed only at the 24 h time point indicates
firstly that it may be of clinical significance (since the level
Table 1 e A, Dose modifying factors at 37% clonogenic survival (DMF0.37) with 95% confidence intervals for CSC and differentiated tumour cell
cultures (diff) of R10, G7 and E2 indicating that CSC cultures are significantly more radioresistant than differentiated tumour cell cultures in both
cell lines. DMF0.37 values were calculated from clonogenic survival data fitted to a linear quadratic model as shown in Figure 1. B, Mean surviving
fractions at 4 Gy (SF4Gy) with 95% confidence intervals for CSC and differentiated tumour cell E2, G7 and R10 cultures. Means of 9 independent
experiments each performed in triplicate for E2 and G7, and means of 3 independent experiments in triplicate for the R10 cell line. P values for 2
sample t test of mean SF4Gy are also shown.
A
DMF 0.37 (95% CI)
E2 CSC vs diff 1.30 (1.16, 1.44) (p < 0.001)
G7 CSC vs diff 1.52 (1.10, 1.93) (p ¼ 0.015)
R10 CSC vs diff 1.47 (1.41, 1.54) (p < 0.0001)
B
E2 CSC E2 diff G7 CSC G7 diff R10 CSC R10 diff
Mean SF 4 Gy (95% CI) 0.62 (0.56, 0.69) 0.46 (0.41, 0.51) 0.63 (0.52, 0.75) 0.46 (0.33, 0.58) 0.28 (0.21, 0.35) 0.11 (0.053, 0.16)
T test of means p ¼ 0.001 p ¼ 0.05 p ¼ 0.018
Figure 2 e A Interrogation of the G2/M checkpoint in E2, G7 and S2 CSC and differentiated tumour cell populations by FACS analysis of mitotic
cells detected by immunostaining for phosphorylated Histone H3 at 0, 3 and 6 h following 5 Gy irradiation in E2 and G7, and 1, 2 and 3 h
following 5 Gy irradiation in S2. Mean values plus SEM of 3 independent experiments are shown after normalisation to unirradiated control
values. B Quantification of gamma H2AX foci detected by immunofluorescence in E2 CSC and differentiated tumour cells following irradiation.
Cells were fixed at time points of 0, 1, 3 and 24 h following 1 Gy and then stained for the DNA double strand break marker gamma H2AX. Nuclei
were stained for CENPF, a G2 cell cycle marker, and foci quantified separately in i. CENPF negative and ii. CENPF positive cells to allow
exclusion of cell cycle effects on foci number. gamma H2AX foci were identified and quantified using Volocity software. Box and whisker plots
represent results of 3 independent experiments. P values calculated by Mann Whitney test.
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both in vitro and in vivo, Banath et al., 2004), and secondly that
the previously noted upregulation of ATM signalling may
contribute to the specific DNA repair phenotype observed in
our GBM CSC populations, since ATM has a specific role in
‘slow’ repair of DSB (Goodarzi et al., 2010; Kuhne et al., 2004).
3.4. Upregulated DDR in GBM CSCs can be effectively
abrogated by ATM kinase inhibition
Given that GBM CSCs have an upregulated ATM response
following ionising radiation, we hypothesised that inhibition
of ATM kinase activity by the commercially available and
well characterised inhibitor KU-55933 would result in modifi-
cation of their radioresistant phenotype. Pre-treatment with
10 mM KU-55933 for 1 h resulted in complete inhibition of
ATM mediated phosphorylation of Chk2 at threonine 68 in
both E2 and G7 CSC and differentiated tumour cell cultures
in response to irradiation (5 Gy, Figure 3A and B). RadiationFigure 3 e Effect of KU-55933 on ATM and Chk2 phosphorylation and t
Western blots previously shown in Figure 2A are shown in A. G7 and B. E2
55933 for 1 h prior to irradiation (5 Gy) and lysed at the time points shown
analysis of mitotic cells identified by positive immunostaining of phosphory
prior to irradiation with 5 Gy in the C. E2 and D. G7 CSC and differenti
independent experiments.induced autophosphorylation of ATM at serine 1981 was
also markedly reduced by KU-55933 in all four populations
(Figure 3A and B). The effects of ATM kinase inhibition on
viability and proliferation of GBM CSC and differentiated
tumour cell cultures were investigated using a CellTiter-
Glo cell proliferation assay (Supplementary Figure 2A and
B). This demonstrated that 10 mM KU-55933 had no significant
cytotoxic effect on CSC or differentiated tumour cell popula-
tions when cells were treated for 24 h or 6 days. Next we
investigated the effect of ATM inhibition on radiation
induced G2/M arrest (Figure 3C and D). In E2 CSC enriched
cultures the enhanced G2/M checkpoint activation observed
previously was only partially abrogated by 10 mM KU-55933
whereas in E2 differentiated tumour cell cultures more pro-
nounced inhibition was demonstrated at all time points
following radiation treatment. A similar trend was seen in
the G7 cell populations. Hence G2/M arrest after radiation
in CSC cultures appears to be only partly sensitive to ATM ki-
nase inhibition.he G2/M checkpoint following ionising radiation. Extensions of the
, CSC and differentiated tumour cell cultures treated with 10 mMKU-
following irradiation. Interrogation of the G2/M checkpoint by FACS
lated Histone H3 following treatment with 10 mM KU-55933 for 1 h
ated tumour cell cultures. Data points represent mean and SEM of 3
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enriched cultures
The radiosensitising effects of KU-55933 were then investi-
gated in GBM CSC and differentiated tumour cell populations
using the clonogenic survival assay. Very marked radiosensi-
tisation of GBM CSCs was observed in R10, E2 and G7 cell lines
(Figure 4A, Table 2). Sensitiser enhancement ratios at 37% sur-
vival (SER0.37) were 2.60 (1.72, 3.4) for E2 CSCs compared with
2.01 (1.27, 2.86) for E2 differentiated tumour cells and 3.17
(2.63, 3.71) for R10 CSCs compared with 2.23 (2.16, 2.30) for
R10 differentiated tumour cells. Potent radiosensitisation
was observed in both CSC and differentiated G7 cells with
SER0.37 values of 3.46 (1.75, 5.18) and 3.43 (1.99, 4.86) respec-
tively. ATM inhibition in the absence of radiation had no effect
on clonogenic survival of any of the six populations. SF4Gy
values were significantly reduced by KU-55933 in CSC and
differentiated tumour cell cultures in R10, E2 and G7 cell lines
(Table 2).
To confirm the effects of ATM inhibition and radiation on
GBM CSC survival we conducted neurosphere formation as-
says in E2 and G7 CSC populations. The extent to whichFigure 4 e Effects of KU-55933 on radiosensitivity of E2, R10 and G7 cel
plus radiation versus radiation alone on CSC and differentiated tumour cell
formation at 0 and 4 Gy are also shown. B, Neurosphere formation assay in
plates and treated with KU-55933 or DMSO prior to irradiation with 2 Gy
under 53 magnification. Mean plus SEM of 3 independent experiments sh
controls: E2 [ 18.56% (15.72, 21.40), G7 [ 34.74% (28.50, 40.98). Repreradiation (2 Gy) inhibited neurosphere formation in vitro was
significantly increased by treatment with 10 mM KU-55933 in
both E2 and G7 CSC populations (Figure 4B). ATM inhibition
in the absence of radiation did not affect neurosphere forma-
tion, and neither KU-55933 nor radiation treatment affected
neurosphere diameter or morphology.
3.6. The enhanced ability of E2 stem cultures to resolve
gamma H2AX foci at 24 h post irradiation is effectively
abrogated by inhibition of ATM
Since ATM inhibition had only amodest effect on G2/M check-
point integrity in CSC we investigated whether the profound
effects of KU-55933 on the radiation sensitivity of CSC could
be explained by modulation of DNA DSB repair. As before,
gamma H2AX foci in G1 and G2 phase populations of E2 cells
were analysed separately and compared between GBM CSC
and differentiated tumour cell cultures.
As expected, ATM inhibition caused a significant reduction
in gamma H2AX foci in unirradiated E2 cells and at early time
points after IR (up to 3 h) in all experiments (Figure 5A and B).
This is consistent with ATM being the major phosphorylatorl lines. A, Clonogenic survival curves comparing effects of KU-55933
cultures in E2, R10 and G7 cell lines. Representative images of colony
E2 and G7 CSC cultures. 10 cells per well were seeded into 96 well
. Neurospheres were quantified manually after 3 (G7) or 4 weeks (E2)
own, normalised to control values. Neurosphere forming efficiency of
sentative images of neurospheres are shown.
Table 2 e Sensitiser enhancement ratios at 37% clonogenic survival
(SER0.37) and SF4Gy values for KU-55933 treatment in combination
with radiation. SER0.37 values were calculated from clonogenic
survival data fitted to a linear quadratic model as shown in Figure 1.
Mean SF4Gy values for CSC and differentiated tumour cell E2, R10
and G7 populations in the absence and presence of KU-55933 (plus
95% CI’s; 3 independent experiments each in triplicate).
SER 0.37
(95% CI)
SF 4 Gy
(eKU-55933)
(95% CI)
SF 4 Gy
(þKU-55933)
(95% CI)
E2 CSC 2.60 (1.72, 3.40) 0.67 (0.52, 0.83) 0.088 (0.037, 0.14)
E2 bulk 2.01 (1.27, 2.86) 0.48 (0.43, 0.53) 0.11 (0.030, 0.18)
G7 CSC 3.46 (1.75, 5.18) 0.83 (0.69, 0.97) 0.096 (0.074, 0.12)
G7 bulk 3.43 (1.99, 4.86) 0.66 (0.54, 0.77) 0.034 (0, 0.1)
R10 CSC 3.17 (2.63, 3.71) 0.28 (0.21, 0.35) 0.12 (0.099, 0.12)
R10 bulk 2.23 (2.16, 2.30) 0.11 (0.053, 0.16) 0
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nalling at DSB rather than reduced numbers of DSB. Hence it
was not possible to interrogate the impact of ATM inhibition
on DSB induction or early repair dynamics using this tech-
nique. In an attempt to address this issue, neutral comet as-
says were undertaken but were not sufficiently sensitive to
provide useful information (data not shown).
Distinct effects of ATM inhibition were observed at later
time points, however. In the CENPF negative CSC population
KU-55933 treatment was associated with a statisticallyFigure 5 e Quantification of gamma H2AX foci in E2 CSC and differentia
radiation. Median number of foci per nucleus in A. CENPF negative CSC a
and B. CENPF positive CSC and differentiated tumour cells following irr
from 3 independent experiments, p values calculated by Mann Whitney Usignificant increase in unresolved gamma H2AX foci at 24 h,
an effect that was not apparent in the differentiated tumour
cell population (Figure 5A).
In CENPF positive populations, KU-55933 was associated
with a statistically significant increase in unresolved gamma
H2AX foci at 24 h in both CSC and differentiated tumour cell
populations (Figure 5B). These data indicate that ATM inhibi-
tion significantly retards repair of the subset of radiation
induced DSB that is resolved with slow kinetics, an effect
that was particularly marked in CSC populations and only
observed in G2 phase cells in differentiated tumour cell
populations.4. Discussion
The aim of this study was to present a detailed and clinically
relevant analysis of radiation responses in GBM CSCs and to
characterise the effects of chemical inhibition of ATM on
these parameters. Investigation of primary GBM cell lines
propagated as paired CSC and differentiated tumour cell cul-
tures permitted direct comparison of the radiation responses
of GBM CSC and non-CSC populations, in contrast to previous
studies which have relied upon comparisons between cell
lines from different parental tumours or comparison of pri-
mary CSC enriched populations to established cell lines
(McCord et al., 2009; Ropolo et al., 2009).ted tumour cells following treatment with 10 mM KU-55933 and 1 Gy
nd differentiated tumour cells following irradiation ±10 mMKU-55933
adiation ±10 mM KU-55933. Box and whisker plots represent results
test.
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 9 2e2 0 3 201In keeping with the seminal observations of Bao and col-
leagues (Bao et al., 2006), direct comparison of clonogenic sur-
vival between paired CSC and differentiated tumour cell
cultures indicated that GBM does indeed contain radioresist-
ant tumour-propagating sub-clones. Clonogenic survival as-
says are the gold standard in vitro measurement of
radiosensitivity, and have been shown to correlate with clin-
ical outcome (Bjork-Eriksson et al., 2000, 1998; West et al.,
1997). Our data support the widely stated yet still contentious
theory that radioresistance of CSCsmakes a significant contri-
bution to treatment failure in GBM.
To elucidate the factors underlying this radioresistance we
performed a detailed quantification of gamma H2AX foci res-
olution in CSC and differentiated tumour cell populations
originating from the same parental tumour. Gamma H2AX
foci formation is observed following DSB generation after ion-
ising radiation exposure and is a sensitive and specific indica-
tor of DSBs (Sedelnikova et al., 2002). Quantification of residual
foci 24 h after irradiation has been shown to correlate with
other measures of radiosensitivity including SF2Gy (Banath
et al., 2004). We demonstrated a small but significant
enhancement of DSB repair 24 h post irradiation in CSCs
compared to differentiated tumour cells. Other investigators
have used alkaline comet assay to measure DNA repair in
CSC’s, which quantifies SSBs and other non-lethal DNA dam-
age. Ropolo et al. conducted an examination of gamma H2AX
foci in sorted CD133 positive and CD133 negative cells and
found no evidence of enhanced repair in the CD133 population
(Ropolo et al., 2009). However the investigators did not quan-
tify the number of foci per nucleus, instead relying upon per-
centage of cells with foci as a surrogate measure. This may
explain why our detailed analysis has detected subtle differ-
ences between CSC and differentiated tumour cell popula-
tions. The differences in foci resolution at 24 h are small but
are likely to have radiobiological significance. It is clear that
a single unrepaired DSB can be lethal to a cancer cell
(Schwager, 1982) and the marked radiosensitivity of ATM or
Artemis deficient cells is associated with failure to repair
only about 10% of radiation induced DSB (Riballo et al.,
2004). The number of excess unresolved DSBs we observed
in E2 differentiated tumour cells compared with CSC equates
to approximately 5% of the induced DSB burden.
Biochemical interrogation of DDR proteins showed that
CSC populations exhibited upregulation of phosphorylated
ATM and Chk2 either at baseline or in response to radiation,
which is in keeping with the published literature (Bao et al.,
2006). We also observed significant differences in G2/M check-
point kinetics following radiation: CSC populations activated
the G2/M checkpoint more proficiently than differentiated
tumour cell populations over a 6 h period post irradiation,
which would allow additional time for DSB repair in CSCs
and contribute to their radioresistant phenotype.
Since radioresistance of CSC populations was associated
with enhanced DSB repair and augmented G2/M checkpoint
activation, ATM represents a very promising target. ATM is a
major hub of the DDR, modulating activity of many proteins
in response to DSBs (Shiloh and Ziv, 2013). ATM has a clearly
defined function in initiating early G2/M checkpoint arrest
following ionising radiation (Xu et al., 2002) and also has
important roles in the repair of a subset of DNA lesionsrepresenting 10e15% of radiation-induced DSB. This subset is
thought to comprise heterochromatic (Goodarzi et al., 2008)
and/or other complex DSBs (Alvarez-Quilon et al., 2014;
Riballo et al., 2004). Defects in ATM function manifest as a
deficit in the slow phase of DSB repair, which is most evident
24 h after radiation (Goodarzi et al., 2010; Kuhne et al., 2004).
As well as abrogation of radiation induced ATM autophos-
phorylation at serine 1981, we observed complete inhibition of
phosphorylation of Chk2 at threonine 68 (a major phosphory-
lation target of ATM) in the presence of the ATM inhibitor KU-
55933. These effects were sustained up to 6 h following radia-
tion. Consistent with these observations the G2/M checkpoint
was almost completely abrogated in both E2 and G7 differen-
tiated tumour cell populations. In contrast, only partial inhibi-
tion of the G2/M checkpoint was observed in CSC populations.
This unexpected observation indicates that CSCs possess ATM
independent mechanisms for activation and maintenance of
the G2/M checkpoint, whereas differentiated tumour cell pop-
ulations appear to be more reliant on ATM function for G2/M
checkpoint integrity. Ataxia telangiectasia related protein
(ATR) is an obvious candidate for the backup role (Fokas
et al., 2014) but as yet no data is available to verify this pro-
posed function.
ATM inhibition was extremely effective in overcoming the
inherent radioresistance of GBM CSCs. SER0.37 values were in
the range of 2e3.5, which is significantly greater than the
enhancement achieved by radiosensitisers in current clinical
use. Golding et al. (Golding et al., 2012) reported similar radio-
sensitisation in established GBM cell lines using inhibitors of
ATM, however our study represents the first analysis of ATM
inhibition in CSCs by clonogenic assay. Raso et al. (Raso
et al., 2012) investigated the sensitising effects of ATM on
GBM CSC and differentiated tumour cells using an MTT assay;
this showed ATM inhibition to have a protective effect on sur-
vival of differentiated tumour cells whereas CSCs were sensi-
tised. We have identified a profound radiosensitising effect of
ATM inhibition on differentiated tumour cells as well as CSC
populations. Clonogenic survival assays are the gold standard
for measuring radiobiological effects and the differing results
may reflect use of a more robust assay, or be cell line depen-
dent. However it is difficult to relate the profound effects of
ATM inhibition on the DDR to a radioprotective effect. Inter-
estingly in E2 cells, ATM inhibition seemed to completely
abrogate the relative radioresistance of CSC’s, with the sur-
vival curve of the KU-55933 treated CSCs being superimposed
on that of the KU-55933 sensitised E2 differentiated tumour
cells. This finding indicates that ATM function is the dominant
component of CSC radioresistance in this cell line.
The influence of ATM inhibition on DNA repair was inves-
tigated in the E2 cell line by quantification of gamma H2AX
foci. ATM is known to be a key phosphorylator of histone
H2AX at early time points following irradiation, however
DNAPK and ATR can contribute to this function (Burma
et al., 2001). Correspondingly inhibition of foci formation
was observed up to 3 h post irradiation in KU-55933 treated
cells, which is likely to represent inhibition of signalling path-
ways responsible for phosphorylation of H2AX rather than
reduced DSB formation. The assessment of DNA repair ki-
netics via analysis of gamma H2AX foci formation and resolu-
tion relies upon post translational modifications and is
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direct assessment of religation of broken DNA ends. Resolu-
tion and formation of gamma H2AX foci can be altered by
manipulation of phosphatases without necessarily reflecting
repair of the underlying DNA DSB (Goldstein et al., 2013;
Kinner et al., 2008). This supports our view that the reduction
in foci formation under conditions of ATM inhibition at early
timepoints following radiation reflects reduced gamma
H2AX formation rather than reduced DNA DSB induction. At
the 24 h time point we observed a significant increase in resid-
ual gamma H2AX foci in CSCs in both G1 and G2 cell popula-
tions, which is highly likely to make a major contribution to
the radiosensitising effects of KU-55933. In differentiated
tumour cells this increase was only evident in the G2 popula-
tion. We have therefore identified a likely mechanism for the
enhanced radiosensitisation of CSCs in the E2 cell line.
Biddlestone-Thorpe and colleagues (Biddlestone-Thorpe
et al., 2013) demonstrated ATM inhibition in an orthotopic
xenograft glioma model in vivo using the ATM inhibitor KU-
60019 delivered via an intracranial pump. They found that sur-
vival was prolonged 2e3 fold by ATM inhibition and radio-
therapy versus controls. This study also showed that
radiosensitisation was influenced by p53 status. This may
have important implications for tumour specificity, since sur-
rounding normal tissue will be p53 wild type and thus ex-
pected to experience less radiosensitisation. Other
investigators have also shown that astrocytes in the brain (a
critical normal supporting tissue) exhibit downregulated
ATM (Gosink et al., 1999; Schneider et al., 2012) and are not
radiosensitised by ATM deficiency. More work is required to
investigate the possible toxic effects of radiation and ATM in-
hibition; however these studies suggest that GBMmay be pref-
erentially radiosensitised in comparison to normal tissue.
A recent study (Venere et al., 2014) describes a key role of
the SSBR protein PARP-1 in the constitutive DDR activation
and relative radioresistance of GBM CSCs. In conjunction
with our findings this paper reinforces the importance of the
DDR in GBM CSC treatment resistance and underlines the po-
tential of selective DDR kinase inhibitors to improve the effi-
cacy of radiotherapy in this setting.
These findings have considerable implications for theman-
agement of GBM in patients. We have illustrated the radiore-
sistance of GBM CSCs and confirmed that enhanced DDR
plays a large part in this radioresistance. Furthermore our in-
vestigations confirm that GBM CSCs have enhanced check-
point activation and DSB repair which is ATM dependent.
Our results add to the growing body of evidence that CSC resis-
tanceplaysan importantpart in the failureof current therapies
to achieve local control in GBM. Most importantly we demon-
strate that potent radiosensitising effects can be achieved in
GBM CSCs by chemical inhibition of ATM. In conclusion, DDR
modulation is a promising therapeutic strategy for the treat-
ment of radioresistant solid tumours, particularly GBM.Appendix A.
Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.molonc.2014.08.003.R E F E R E N C E S
Alvarez-Quilon, A., Serrano-Benitez, A., Lieberman, J.A.,
Quintero, C., Sanchez-Gutierrez, D., Escudero, L.M., Cortes-
Ledesma, F., 2014. ATM specifically mediates repair of double-
strand breaks with blocked DNA ends. Nat. Commun. 5, 3347.
Banath, J.P., Macphail, S.H., Olive, P.L., 2004. Radiation sensitivity,
H2AX phosphorylation, and kinetics of repair of DNA strand
breaks in irradiated cervical cancer cell lines. Cancer Res. 64,
7144e7149.
Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B.,
Dewhirst, M.W., Bigner, D.D., Rich, J.N., 2006. Glioma stem
cells promote radioresistance by preferential activation of the
DNA damage response. Nature 444, 756e760.
Bartkova, J., Hamerlik, P., Stockhausen, M.T., Ehrmann, J.,
Hlobilkova, A., Laursen, H., Kalita, O., Kolar, Z., Poulsen, H.S.,
Broholm, H., Lukas, J., Bartek, J., 2010. Replication stress and
oxidative damage contribute to aberrant constitutive
activation of DNA damage signalling in human gliomas.
Oncogene 29, 5095e5102.
Bartkova, J., Horejsi, Z., Koed, K., Kramer, A., Tort, F., Zieger, K.,
Guldberg, P., Sehested, M., Nesland, J.M., Lukas, C., Orntoft, T.,
Lukas, J., Bartek, J., 2005. DNA damage response as a candidate
anti-cancer barrier in early human tumorigenesis. Nature 434,
864e870.
Beier, D., Hau, P., Proescholdt, M., Lohmeier, A., Wischhusen, J.,
Oefner, P.J., Aigner, L., Brawanski, A., Bogdahn, U., Beier, C.P.,
2007. CD133(þ) and CD133() glioblastoma-derived cancer
stem cells show differential growth characteristics and
molecular profiles. Cancer Res. 67, 4010e4015.
Biddlestone-Thorpe, L., Sajjad, M., Rosenberg, E., Beckta, J.M.,
Valerie, N.C., Tokarz, M., Adams, B.R., Wagner, A.F., Khalil, A.,
Gilfor, D., Golding, S.E., Deb, S., Temesi, D.G., Lau, A.,
O’Connor, M.J., Choe, K.S., Parada, L.F., Lim, S.K.,
Mukhopadhyay, N.D., Valerie, K., 2013. ATM kinase inhibition
preferentially sensitizes p53-mutant glioma to ionizing
radiation. Clin. Cancer Res.: An Official Journal of the
American Association for Cancer Research 19, 3189e3200.
Bjork-Eriksson, T., West, C., Karlsson, E., Mercke, C., 2000. Tumor
radiosensitivity (SF2) is a prognostic factor for local control in
head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys. 46,
13e19.
Bjork-Eriksson, T., West, C.M., Karlsson, E., Slevin, N.J.,
Davidson, S.E., James, R.D., Mercke, C., 1998. The in vitro
radiosensitivity of human head and neck cancers. Br. J. Cancer
77, 2371e2375.
Bonavia, R., Inda, M.M., Cavenee, W.K., Furnari, F.B., 2011.
Heterogeneity maintenance in glioblastoma: a social network.
Cancer Res. 71, 4055e4060.
Burma, S., Chen, B.P., Murphy, M., Kurimasa, A., Chen, D.J., 2001.
ATM phosphorylates histone H2AX in response to DNA
double-strand breaks. J. Biol. Chem. 276, 42462e42467.
Chen, J., Li, Y., Yu, T.S., McKay, R.M., Burns, D.K., Kernie, S.G.,
Parada, L.F., 2012. A restricted cell population propagates
glioblastoma growth after chemotherapy. Nature 488,
522e526.
Fael Al-Mayhani, T.M., Ball, S.L., Zhao, J.W., Fawcett, J.,
Ichimura, K., Collins, P.V., Watts, C., 2009. An efficient method
for derivation and propagation of glioblastoma cell lines that
conserves the molecular profile of their original tumours.
J. Neurosci. Methods 176, 192e199.
Fokas, E., Prevo, R., Hammond, E.M., Brunner, T.B.,
McKenna, W.G., Muschel, R.J., 2014. Targeting ATR in DNA
damage response and cancer therapeutics. Cancer Treat. Rev.
40, 109e117.
Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S.,
Fiocco, R., Foroni, C., Dimeco, F., Vescovi, A., 2004. Isolation and
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 9 2e2 0 3 203characterization of tumorigenic, stem-like neural precursors
from human glioblastoma. Cancer Res. 64, 7011e7021.
Golding, S.E., Rosenberg, E., Adams, B.R., Wignarajah, S.,
Beckta, J.M., O’Connor, M.J., Valerie, K., 2012. Dynamic
inhibition of ATM kinase provides a strategy for glioblastoma
multiforme radiosensitization and growth control. Cell Cycle
11, 1167e1173.
Golding, S.E., Rosenberg, E., Valerie, N., Hussaini, I., Frigerio, M.,
Cockcroft, X.F., Chong, W.Y., Hummersone, M., Rigoreau, L.,
Menear, K.A., O’Connor, M.J., Povirk, L.F., van Meter, T.,
Valerie, K., 2009. Improved ATM kinase inhibitor KU-60019
radiosensitizes glioma cells, compromises insulin, AKT and
ERK prosurvival signaling, and inhibits migration and
invasion. Mol. Cancer Ther. 8, 2894e2902.
Goldstein, M., Derheimer, F.A., Tait-Mulder, J., Kastan, M.B., 2013.
Nucleolin mediates nucleosome disruption critical for DNA
double-strand break repair. Proc. Natl. Acad. Sci. USA 110,
16874e16879.
Goodarzi, A.A., Jeggo, P., Lobrich, M., 2010. The influence of
heterochromatin on DNA double strand break repair: getting
the strong, silent type to relax. DNA Repair 9, 1273e1282.
Goodarzi, A.A., Noon, A.T., Deckbar, D., Ziv, Y., Shiloh, Y.,
Lobrich, M., Jeggo, P.A., 2008. ATM signaling facilitates repair
of DNA double-strand breaks associated with
heterochromatin. Mol. Cell 31, 167e177.
Gosink, E.C., Chong, M.J., McKinnon, P.J., 1999. Ataxia
telangiectasia mutated deficiency affects astrocyte growth but
not radiosensitivity. Cancer Res. 59, 5294e5298.
Joo, K.M., Kim, S.Y., Jin, X., Song, S.Y., Kong, D.S., Lee, J.I.,
Jeon, J.W., Kim, M.H., Kang, B.G., Jung, Y., Jin, J., Hong, S.C.,
Park, W.Y., Lee, D.S., Kim, H., Nam, D.H., 2008. Clinical and
biological implications of CD133-positive and CD133-negative
cells in glioblastomas. Lab. Invest.: A Journal of Technical
Methods and Pathology 88, 808e815.
Kelly, J.J., Stechishin, O., Chojnacki, A., Lun, X., Sun, B.,
Senger, D.L., Forsyth, P., Auer, R.N., Dunn, J.F., Cairncross, J.G.,
Parney, I.F., Weiss, S., 2009. Proliferation of human
glioblastoma stem cells occurs independently of exogenous
mitogens. Stem Cells 27, 1722e1733.
Kinner, A., Wu, W., Staudt, C., Iliakis, G., 2008. Gamma-H2AX in
recognition and signaling of DNA double-strand breaks in the
context of chromatin. Nucleic Acids Res. 36, 5678e5694.
Kuhne, M., Riballo, E., Rief, N., Rothkamm, K., Jeggo, P.A.,
Lobrich, M., 2004. A double-strand break repair defect in ATM-
deficient cells contributes to radiosensitivity. Cancer Res. 64,
500e508.
Mannino, M., Gomez-Roman, N., Hochegger, H., Chalmers, A.J.,
2014. Differential sensitivity of Glioma stem cells to Aurora
kinase A inhibitors: implications for stem cell mitosis and
centrosome dynamics. Stem Cell Res. 13, 135e143.
McCord, A.M., Jamal, M., Williams, E.S., Camphausen, K.,
Tofilon, P.J., 2009. CD133þ glioblastoma stem-like cells are
radiosensitive with a defective DNA damage response
compared with established cell lines. Clin. Cancer Res.: An
Official Journal of the American Association for Cancer
Research 15, 5145e5153.
Nowell, P.C., 1976. The clonal evolution of tumor cell populations.
Science 194, 23e28.
Patel, A.P., Tirosh, I., Trombetta, J.J., Shalek, A.K., Gillespie, S.M.,
Wakimoto, H., Cahill, D.P., Nahed, B.V., Curry, W.T.,
Martuza, R.L., Louis, D.N., Rozenblatt-Rosen, O., Suva, M.L.,
Regev, A., Bernstein, B.E., 2014. Single-cell RNA-seq highlights
intratumoral heterogeneity in primary glioblastoma. Science
344, 1396e1401.
Raso, A., Vecchio, D., Cappelli, E., Ropolo, M., Poggi, A., Nozza, P.,
Biassoni, R., Mascelli, S., Capra, V., Kalfas, F., Severi, P.,Frosina, G., 2012. Characterization of glioma stem cells
through multiple stem cell markers and their specific
sensitization to double-strand break-inducing agents by
pharmacological inhibition of ataxia telangiectasia mutated
protein. Brain Pathol. 22, 677e688.
Reya, T., Morrison, S.J., Clarke, M.F., Weissman, I.L., 2001. Stem
cells, cancer, and cancer stem cells. Nature 414, 105e111.
Riballo, E., Kuhne, M., Rief, N., Doherty, A., Smith, G.C., Recio, M.J.,
Reis, C., Dahm, K., Fricke, A., Krempler, A., Parker, A.R.,
Jackson, S.P., Gennery, A., Jeggo, P.A., Lobrich, M., 2004. A
pathway of double-strand break rejoining dependent upon
ATM, Artemis, and proteins locating to gamma-H2AX foci.
Mol. Cell 16, 715e724.
Ropolo, M., Daga, A., Griffero, F., Foresta, M., Casartelli, G.,
Zunino, A., Poggi, A., Cappelli, E., Zona, G., Spaziante, R.,
Corte, G., Frosina, G., 2009. Comparative analysis of DNA
repair in stem and nonstem glioma cell cultures. Mol. Cancer
Res.: MCR 7, 383e392.
Schneider, L., Fumagalli, M., d’Adda di Fagagna, F., 2012.
Terminally differentiated astrocytes lack DNA damage
response signaling and are radioresistant but retain DNA
repair proficiency. Cell Death Differ. 19, 582e591.
Schwager, F., 1982. Irreparable dna double strand dna breaks
induced in eukaryotic cells by sparsely or densely ionizing
radiation and their importance for cell killing. Mutat. Res. 96.
Sedelnikova, O.A., Rogakou, E.P., Panyutin, I.G., Bonner, W.M.,
2002. Quantitative detection of (125)IdU-induced DNA double-
strand breaks with gamma-H2AX antibody. Radiat. Res. 158,
486e492.
Shiloh, Y., Ziv, Y., 2013. The ATM protein kinase: regulating the
cellular response to genotoxic stress, and more. Nat. Rev. Mol.
Cell Biol. 14, 197e210.
Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J.,
Hide, T., Henkelman, R.M., Cusimano, M.D., Dirks, P.B., 2004.
Identification of human brain tumour initiating cells. Nature
432, 396e401.
Son, M.J., Woolard, K., Nam, D.H., Lee, J., Fine, H.A., 2009. SSEA-1
is an enrichment marker for tumor-initiating cells in human
glioblastoma. Cell Stem Cell 4, 440e452.
Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B.,
Taphoorn, M.J., Belanger, K., Brandes, A.A., Marosi, C.,
Bogdahn, U., Curschmann, J., Janzer, R.C., Ludwin, S.K.,
Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J.G.,
Eisenhauer, E., Mirimanoff, R.O.European Organisation for, R.,
Treatment of Cancer Brain, T., Radiotherapy, G., National
Cancer Institute of Canada Clinical Trials, G., 2005.
Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N. Engl. J. Med. 352, 987e996.
Taylor, A.M., Harnden, D.G., Arlett, C.F., Harcourt, S.A.,
Lehmann, A.R., Stevens, S., Bridges, B.A., 1975. Ataxia
telangiectasia: a human mutation with abnormal radiation
sensitivity. Nature 258, 427e429.
Venere, M., Hamerlik, P., Wu, Q., Rasmussen, R.D., Song, L.A.,
Vasanji, A., Tenley, N., Flavahan, W.A., Hjelmeland, A.B.,
Bartek, J., Rich, J.N., 2014. Therapeutic targeting of constitutive
PARP activation compromises stem cell phenotype and
survival of glioblastoma-initiating cells. Cell Death Differ. 21,
258e269.
West, C.M., Davidson, S.E., Roberts, S.A., Hunter, R.D., 1997. The
independence of intrinsic radiosensitivity as a prognostic
factor for patient response to radiotherapy of carcinoma of the
cervix. Br. J. Cancer 76, 1184e1190.
Xu, B., Kim, S.T., Lim, D.S., Kastan, M.B., 2002. Two molecularly
distinct G(2)/M checkpoints are induced by ionizing
irradiation. Mol. Cell. Biol. 22, 1049e1059.
